ADPT Relative Valuation
ADPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADPT is overvalued; if below, it's undervalued.
Historical Valuation
Adaptive Biotechnologies Corp (ADPT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -11.65. The fair price of Adaptive Biotechnologies Corp (ADPT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：16.68
Fair
-27.71
PE
1Y
3Y
5Y
Trailing
Forward
-117.03
EV/EBITDA
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBITDA of -117.03. The 5-year average EV/EBITDA is -20.92. The thresholds are as follows: Strongly Undervalued below -72.12, Undervalued between -72.12 and -46.52, Fairly Valued between 4.68 and -46.52, Overvalued between 4.68 and 30.29, and Strongly Overvalued above 30.29. The current Forward EV/EBITDA of -117.03 falls within the Strongly Undervalued range.
-26.35
EV/EBIT
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBIT of -26.35. The 5-year average EV/EBIT is -10.11. The thresholds are as follows: Strongly Undervalued below -28.08, Undervalued between -28.08 and -19.09, Fairly Valued between -1.12 and -19.09, Overvalued between -1.12 and 7.86, and Strongly Overvalued above 7.86. The current Forward EV/EBIT of -26.35 falls within the Undervalued range.
10.30
PS
Adaptive Biotechnologies Corp. (ADPT) has a current PS of 10.30. The 5-year average PS is 12.14. The thresholds are as follows: Strongly Undervalued below -14.97, Undervalued between -14.97 and -1.42, Fairly Valued between 25.69 and -1.42, Overvalued between 25.69 and 39.24, and Strongly Overvalued above 39.24. The current Forward PS of 10.30 falls within the Historic Trend Line -Fairly Valued range.
-63.32
P/OCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/OCF of -63.32. The 5-year average P/OCF is -17.17. The thresholds are as follows: Strongly Undervalued below -49.58, Undervalued between -49.58 and -33.38, Fairly Valued between -0.96 and -33.38, Overvalued between -0.96 and 15.25, and Strongly Overvalued above 15.25. The current Forward P/OCF of -63.32 falls within the Strongly Undervalued range.
-89.03
P/FCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/FCF of -89.03. The 5-year average P/FCF is -37.01. The thresholds are as follows: Strongly Undervalued below -194.55, Undervalued between -194.55 and -115.78, Fairly Valued between 41.76 and -115.78, Overvalued between 41.76 and 120.53, and Strongly Overvalued above 120.53. The current Forward P/FCF of -89.03 falls within the Historic Trend Line -Fairly Valued range.
Adaptive Biotechnologies Corp (ADPT) has a current Price-to-Book (P/B) ratio of 12.79. Compared to its 3-year average P/B ratio of 4.26 , the current P/B ratio is approximately 199.77% higher. Relative to its 5-year average P/B ratio of 4.79, the current P/B ratio is about 166.84% higher. Adaptive Biotechnologies Corp (ADPT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -17.09%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.40% , the current FCF yield is about -100.00% lower.
13.03
P/B
Median3y
4.26
Median5y
4.79
-2.41
FCF Yield
Median3y
-17.09
Median5y
-14.40
Competitors Valuation Multiple
The average P/S ratio for ADPT's competitors is 0.00, providing a benchmark for relative valuation. Adaptive Biotechnologies Corp Corp (ADPT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 102.38%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADPT increased by 191.24% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -10.86 to -32.98.
The secondary factor is the Revenue Growth, contributed 102.38%to the performance.
Overall, the performance of ADPT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Adaptive Biotechnologies Corp (ADPT) currently overvalued or undervalued?
What is Adaptive Biotechnologies Corp (ADPT) fair value?
How does ADPT's valuation metrics compare to the industry average?
What is the current P/B ratio for Adaptive Biotechnologies Corp (ADPT) as of Dec 05 2025?
What is the current FCF Yield for Adaptive Biotechnologies Corp (ADPT) as of Dec 05 2025?
What is the current Forward P/E ratio for Adaptive Biotechnologies Corp (ADPT) as of Dec 05 2025?